AI
Commented by Armin Schulz on September 15th, 2025 | 07:25 CEST
Beyond FAANG, German tech companies such as SAP, Finexity and TeamViewer also offer potential for your portfolio
While US tech giants like Meta and Google dominate the headlines, other technology companies in Germany receive little attention. But here too, on the other side of the Atlantic, innovative companies with disruptive technologies and robust business models are shaping the future and offering unique opportunities for capital growth. Reason enough to take a closer look at three German companies: SAP, Finexity and TeamViewer. We analyze the strategic decisions and innovations that will shape the next investment success story.
Read
Commented by Armin Schulz on September 12th, 2025 | 07:05 CEST
Investing in the future of medicine: A look at Novo Nordisk, NetraMark Holdings and Evotec
AI is completely transforming the pharmaceutical industry. Modern algorithms sift through vast amounts of data, identify promising therapeutic approaches, and advance drug development at record speed. This increase in efficiency is an absolute game changer. Not only does it save billions, but it also significantly increases success rates and catapults agile companies to the forefront. While cumbersome large corporations laboriously digitize their research departments, disruptive start-ups with innovative AI platforms are shaking up the market. It is precisely this dynamic that presents unique opportunities for investors, if they know how to decipher them. Today, we take a closer look at Danish pharmaceutical giant Novo Nordisk, AI specialist NetraMark Holdings, and German research service provider Evotec.
Read
Commented by Armin Schulz on September 11th, 2025 | 07:15 CEST
The Hidden Champions of 2025: Puma, Sranan Gold and AMD – Where it might be worth getting in
As an investor, it is often wise to find hidden gems rather than buy expensive market leaders. While large corporations are often overvalued, undervalued small caps offer unique opportunities. Whether as turnaround candidates, commodity gems, or technology leaders, these specialized companies have the potential to dominate their niches and initiate a quiet catch-up rally. For savvy investors, this second tier is the real source of above-average returns. Three promising candidates that embody this profile are sporting goods manufacturer Puma, gold explorer Sranan Gold, and chip designer AMD. Let's take a look at their current situation.
Read
Commented by Nico Popp on September 4th, 2025 | 07:25 CEST
AI reaches medicine – Here is where it has the greatest impact: NetraMark, Siemens Healthineers, Intuitive Surgical
AI is revolutionizing more and more industries. A recent article in Handelsblatt highlights the enormous potential in medicine and names Siemens Healthineers and Intuitive Surgical as the beneficiaries. AI would significantly increase the often-lacking efficiency in industry. According to Handelsblatt, citing analysts from Fortune Business Insights, the market for AI in healthcare could grow by 44% annually to USD 504 billion by 2032. We show where the greatest leverage exists and which companies are still small enough to benefit disproportionately from developments in the coming years.
Read
Commented by Nico Popp on September 1st, 2025 | 07:05 CEST
The key to higher returns: How ESG is making Newmont, Intel, and Almonty more successful
Just a few years ago, ESG was a buzzword that companies in industry and mining could use to present themselves in a favorable light. Today, standards for sustainable business practices are clearly defined and bring tangible benefits to all who adhere to them. For example, cooperation with local residents and adherence to high environmental standards at mining companies such as Newmont and Almonty ensure better financing conditions and motivated, skilled workers. Potential customers such as Intel also pay close attention to the conditions under which raw materials are extracted. In this article, we explain how ESG and returns go hand in hand.
Read
Commented by Fabian Lorenz on August 27th, 2025 | 07:20 CEST
Quick 30% return possible? Novo Nordisk, D-Wave, and NetraMark shares!
Three completely different companies, but all with return potential: AI specialist NetraMark is on the verge of a technical breakout. NetraAI has outperformed ChatGPT and DeepSeek and is gaining more customers. If the breakout occurs, the stock could quickly move toward the analyst price target, representing a potential gain of around 30%. At Novo Nordisk, last week's price gains have almost been lost again. Wegovy's strong market entry in South Korea caused only brief jubilation. Now, competition from Eli Lilly is dampening the mood. At D-Wave, the stock could soon be heading toward new highs again. The Company plans to accelerate its growth in Asia, and new momentum for the stock is expected in September.
Read
Commented by Armin Schulz on August 26th, 2025 | 07:10 CEST
The blueprint for AI-driven drug discovery: How Evotec, NetraMark Holdings, and BioNTech are leveraging new opportunities
The pharmaceutical industry is undergoing a revolution. Artificial intelligence is reducing drug discovery times from years to months and dramatically increasing hit rates. Data-driven predictions and virtual simulations are increasingly replacing costly trial-and-error approaches. This technological leap is already generating concrete successes and massive competitive advantages for pioneers who implemented their digitalization strategies early on. Most recently, an AI-designed drug advanced to clinical trials in record time. Three companies driving this change and reaping its benefits are Evotec, NetraMark Holdings, and BioNTech.
Read
Commented by André Will-Laudien on August 21st, 2025 | 07:15 CEST
High-tech correction! A brief pause, then the party continues at Palantir, Deutsche Telekom, MiMedia, and SAP
Oops – there it is. The first correction at Palantir was somewhat severe. But after a 1000% increase in 24 months – who cares? The blockbuster themes of artificial intelligence, cloud computing, and big data continue to dominate the stock market, leading to significant daily price gains. Investors seem to view the capital markets as an almost one-way success story in which valuations play hardly any role. Europe is increasingly taking the lead, with the EURO STOXX 50 rising by around 20% since the tariff dip in April. Despite apparent risks, many investors are sticking to the bull market, although the S&P 500's high Shiller P/E ratio of over 38 is sending out a clear warning signal. Deutsche Telekom is generating excitement with the announcement of another innovation push in the form of its first AI-based smartphone. The coming weeks therefore offer exciting opportunities for investors who, despite the warning signs, are betting on the continued momentum of the market. Where to invest?
Read
Commented by André Will-Laudien on August 21st, 2025 | 07:05 CEST
The AI revolution is turning biotech into a gold mine! BioNTech, Eli Lilly, NetraMark Holdings, and Pfizer know how!
Artificial intelligence (AI) is becoming increasingly important in drug research and is revolutionizing the development of new active ingredients. Machine learning and neural networks enable large amounts of data to be analyzed and potential drugs to be identified more quickly. AI also plays a central role in the planning and execution of clinical trials by recognizing data patterns, identifying suitable patients, and thus increasing the chances of success. The market for AI in drug development is growing rapidly. Experts estimate it will reach several billion US dollars by 2025, with projected annual growth of over 40%. Where are the opportunities and risks for agile investors?
Read
Commented by Stefan Feulner on August 19th, 2025 | 07:20 CEST
JD.com, NetraMark, Palantir – Opportunities in the second tier
The extremely high valuations of the big players in artificial intelligence are a thorn in the side of many analysts. The sharp rise in share prices of Nvidia and Palantir, the latter of which has already reached dot-com status with a current price-to-earnings ratio of no less than 242, means that a healthy consolidation is long overdue. In contrast, AI companies from the second and third tier are standing out, whose potential has so far been largely overlooked by investors.
Read